That is only their employees on the payroll. Much of their product development it outsourced (who knows how many heads are on these teams), their clinical trials will likely be run by a CRO and so on for every needed resource. They will also continually add more employees as they need them. I do agree that they will be acquired, though I think it's more directly involved with having a superb product in a niche market with the high likelihood of disrupting the market share than having limited personnel.
News 
Market Data 
Discover 
AI
